BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

KAEL–GemVax 

912-18 Daechi-Dong
2nd Floor Lia B/D
Gangnam  Seoul    Korea
Phone: 82-2-544-6221 Fax: 82-2-3443-4997


SEARCH JOBS


Industry
Pharmaceutical






 Company News
KAEL–GemVax Release: Final Results From the Phase III TeloVac Trial in Pancreatic Cancer Presented at American Society of Clinical Oncology, Chicago, June 3rd 2013. 6/3/2013 11:08:09 AM    More...
KAEL–GemVax Reports Encouraging Interim Progress in Phase II Study of GV1001 Anti-telomerase Vaccine in NSCLC 11/15/2011 6:27:23 AM    More...
KAEL–GemVax: TeloVac Becomes World’s Largest Ever Pancreatic Cancer Vaccine Trial 5/5/2011 10:58:54 AM    More...
Lytix Biopharma and KAEL–GemVax Announce First Patient Treated in Clinical Trial to Combine LTX-315 and GV1001 Cancer Vaccine Immunotherapy 12/6/2010 11:50:35 AM    More...
KAEL–GemVax Reports Significant Interim Progress In UK Telovac Phase III Study Of GV1001 Anti-Telomerase Vaccine In Pancreatic Cancer 7/12/2010 10:47:47 AM    More...
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy 6/8/2010 10:54:48 AM    More...

//-->